Article and Video CATEGORIES
Drs. Nate Pennell from Cleveland Clinic and Mary Pinder from Moffitt Cancer Center in Tampa, FL sat down with our own Dr. Jack West to discuss early impressions of some of the most provocative research presented at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago in early June.
Here's a growing list of podcasts covering the topics they discussed:
Is it possible to test for biomarkers in lung cancer on a national scale?
Is there a role for molecular markers predicting the best chemotherapy to use in lung cancer?
Can we predict which patients will benefit from Tarceva based on a blood test?
Do you need Avastin in first line and maintenance therapy in advanced NSCLC?
Is there a best Avastin-containing regimen for first line and maintenance therapy in advanced NSCLC?
Can we harness our immune system to fight NSCLC?
Can we improve on XALKORI? New agents for patients with an ALK-1 rearrangement
Is Nintedanib a new agent worthy of becoming a new treatment for advanced NSCLC?
Are molecular markers just for NSCLC?
Could BRAF be a new target in NSCLC?
Can we target KRAS effectively in advanced NSCLC?
What have we learned from the START trial of immunotherapy in locally advanced NSCLC?
How do we approach acquired resistance to targeted therapies in lung cancer?
How should we integrate new immunotherapies into treatment strategies for lung cancer?
Is there a place for maintenance therapy in extensive stage SCLC?
This completes the series. We hope you found this content useful.
We thank Drs. Nate Pennell and Mary Pinder for their generosity with their time and expertise in providing this information to the lung cancer community.
We also thank LUNGevity for sponsoring this video series.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi Bluebird, Welcome to GRACE. I'm sorry you're going through this scare and hope it's just inflammation or from an infection you didn't know you had.
A CT would be...
Radiation + Brain Operation has just been discarded due to high risk. They will double Tagrisso dosis and then wait to see if it works, then try traditional Chemo. I would...
Hi and welcome to GRACE. I'm sorry to know you are entering a new stage. I'm not about to comment just now but wanted to let you know I see your...
Edit to say, we can't give advice but we can comment with views and facts. :)
My first thought is to ask if she has been seen at a large...
Hi Barbro, Welcome to GRACE. I'm sorry you're worrying about this. We aren't able to give feedback on scan reports. Interpreting scan reports in this setting is not only unethical but...
Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...